Skip navigation
  •  Home
  • UDC 
    • Getting started
    • RUC Policies
    • FAQ
    • FAQ on Copyright
    • More information at INFOguias UDC
  • Browse 
    • Communities
    • Browse by:
    • Issue Date
    • Author
    • Title
    • Subject
  • Help
    • español
    • Gallegan
    • English
  • Login
  •  English 
    • Español
    • Galego
    • English
  
View Item 
  •   DSpace Home
  • 1. Investigación
  • Instituto de Investigación Biomédica da Coruña (INIBIC)
  • Viroloxía clínica
  • INIBIC-VC - Artigos
  • View Item
  •   DSpace Home
  • 1. Investigación
  • Instituto de Investigación Biomédica da Coruña (INIBIC)
  • Viroloxía clínica
  • INIBIC-VC - Artigos
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Long-term clinical experience with darunavir (2007–2015) in a large cohort of HIV-infected patients in Spain authors

Thumbnail
View/Open
Pernas_Long.pdf (214.2Kb)
Use this link to cite
http://hdl.handle.net/2183/18373
Collections
  • INIBIC-ECB - Artigos [50]
  • INIBIC-VC - Artigos [37]
Metadata
Show full item record
Title
Long-term clinical experience with darunavir (2007–2015) in a large cohort of HIV-infected patients in Spain authors
Author(s)
Pernas, Berta
Grandal, Marta
Tabernilla, Andrés
Cid-Silva, Purificación
Pértega-Díaz, Sonia
Castro-Iglesias, Ángeles
Mena, Álvaro
Margusino-Framiñán, Luis
Pedreira, José D.
Poveda, Eva
Date
2016-06-06
Citation
Pernas B, Grandal M, Tabernilla A, et al. Long-term clinical experience with darunavir (2007–2015) in a large cohort of HIV-infected patients in Spain authors. J Med Vir. 2016;88(12):2125-31
Abstract
[Abstract] The clinical experience with the protease inhibitor darunavir/ritonavir (DRV/r) was retrospectively evaluated in a cohort of 173 HIV+ patients who initiated antiretroviral treatment including DRV/r (period 2007–2015). The 43.2% had a CD4 nadir ≤100 cells/mm3, 64.1% were treatment-experienced, and 36.5% had failed to >3 lines of antiretroviral therapy. Nonetheless, the rate of virological suppression (HIV-RNA <50 copies/ml) in naïve patients was 63%, 66.7%, and 63.6% at 48, 96, and 144 weeks, respectively. The rate of virological suppression in treatment-experienced patients was 62.7%, 78.7%, and 79.1% at 48, 96, and 144 weeks, respectively. No differences were observed according to the immunovirological status neither dosage of DRV/r. Most of them (82.6%) maintained DRV/r treatment. Causes for DRV/r discontinuation were mainly gastrointestinal and cutaneous adverse events (10.5%), switch to simplification treatment strategies (3.5%) and virological failure (1.7%). These findings demonstrate the prolonged efficacy and tolerability of DRV/r even in multi-treated HIV+ patients with an unfavorable immunovirological status.
Keywords
HIV infection
Darunavir
Efficacy
Safety
 
Editor version
http://dx.doi.org/10.1002/jmv.24585
Rights
This is the peer reviewed version of the article which has been published in final form at Wiley Online Library. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for self-archiving
ISSN
0146-6615
1096-9071
 

Browse

All of DSpaceCommunities & CollectionsBy Issue DateAuthorsTitlesSubjectsThis CollectionBy Issue DateAuthorsTitlesSubjects

My Account

LoginRegister

Statistics

View Usage Statistics
Sherpa
OpenArchives
OAIster
Scholar Google
UNIVERSIDADE DA CORUÑA. Servizo de Biblioteca.    DSpace Software Copyright © 2002-2013 Duraspace - Send Feedback